In the existing literature and established guidelines, routine testing of KRAS is not recommended in the workup of non-metastatic colon cancer due to a lack of evidence in its utility for determination of adjuvant therapy [3,12,64]. This evidence concerns the gene KRAS and malignant colon neoplasm.